Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant hepatitis B vaccine with CpG and aluminum adjuvants using different immunization schedules
ChiCTR2500108408Phase 2Completed
- Sponsor
- Shandong Provincial Center for Disease Control and Prevention
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of recombinant hepatitis B vaccine Bio Farma in hepatitis B (HBV) (3 arms), sponsored by Shandong Provincial Center for Disease Control and Prevention. Primary endpoints: Positive conversion rate of anti-HBs antibody during basic immunization stage and Positive rate of anti-HBs antibody during immune persistence stage. Started Aug 2025; status: completed.
02
Drugs
recombinant hepatitis B vaccine Bio Farma
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2500108408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108408.